Jennifer Scheer, MD | |
739 W Springfield Ave, Gerald, MO 63037-2135 | |
(573) 764-3311 | |
(573) 764-4362 |
Full Name | Jennifer Scheer |
---|---|
Gender | Female |
Speciality | Family Practice |
Experience | 30 Years |
Location | 739 W Springfield Ave, Gerald, Missouri |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1487621256 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Q00000X | Family Medicine | 113151 (Missouri) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Mercy Home Health | Saint louis, MO | Home health agency |
Mercy Hospice | Saint louis, MO | Hospice |
Mercy Hospital Washington | Washington, MO | Hospital |
Mercy Hospital St Louis | Saint louis, MO | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Mercy Clinic East Communities | 7214827922 | 491 |
News Archive
With Covid vaccines expected to remain scarce into early spring, Connecticut has scrapped its complicated plans to prioritize immunizations for people under 65 with certain chronic conditions and front-line workers. Instead, the state will primarily base eligibility on age.
New research published online today in Blood Journal of the American Society of Hematology (ASH), challenges the generally held belief that individuals with HIV and aggressive lymphoma are not candidates for standard treatment.
We commend the U.S. House of Representatives for passing health reform legislation. Our country has a moral imperative to provide affordable access to health care, and this legislation will help do just that through significant improvements to Medicare, Medicaid and long-term care services.
The Alzheimer's Drug Discovery Foundation (ADDF) announced today that it has awarded a grant of $240,000 to AgeneBio Inc. to develop a new class of small-molecules that have promise in treating amnestic mild cognitive impairment (aMCI), a neurological condition that often progresses to Alzheimer's disease and affects more than 3 million aging Americans.
› Verified 6 days ago
Entity Name | Mercy Hospitals East Communities |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1285664177 PECOS PAC ID: 3779479019 Enrollment ID: O20040224001164 |
News Archive
With Covid vaccines expected to remain scarce into early spring, Connecticut has scrapped its complicated plans to prioritize immunizations for people under 65 with certain chronic conditions and front-line workers. Instead, the state will primarily base eligibility on age.
New research published online today in Blood Journal of the American Society of Hematology (ASH), challenges the generally held belief that individuals with HIV and aggressive lymphoma are not candidates for standard treatment.
We commend the U.S. House of Representatives for passing health reform legislation. Our country has a moral imperative to provide affordable access to health care, and this legislation will help do just that through significant improvements to Medicare, Medicaid and long-term care services.
The Alzheimer's Drug Discovery Foundation (ADDF) announced today that it has awarded a grant of $240,000 to AgeneBio Inc. to develop a new class of small-molecules that have promise in treating amnestic mild cognitive impairment (aMCI), a neurological condition that often progresses to Alzheimer's disease and affects more than 3 million aging Americans.
› Verified 6 days ago
Entity Name | Mercy Clinic East Communities |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1073739041 PECOS PAC ID: 7214827922 Enrollment ID: O20070521000058 |
News Archive
With Covid vaccines expected to remain scarce into early spring, Connecticut has scrapped its complicated plans to prioritize immunizations for people under 65 with certain chronic conditions and front-line workers. Instead, the state will primarily base eligibility on age.
New research published online today in Blood Journal of the American Society of Hematology (ASH), challenges the generally held belief that individuals with HIV and aggressive lymphoma are not candidates for standard treatment.
We commend the U.S. House of Representatives for passing health reform legislation. Our country has a moral imperative to provide affordable access to health care, and this legislation will help do just that through significant improvements to Medicare, Medicaid and long-term care services.
The Alzheimer's Drug Discovery Foundation (ADDF) announced today that it has awarded a grant of $240,000 to AgeneBio Inc. to develop a new class of small-molecules that have promise in treating amnestic mild cognitive impairment (aMCI), a neurological condition that often progresses to Alzheimer's disease and affects more than 3 million aging Americans.
› Verified 6 days ago
Mailing Address | Practice Location Address |
---|---|
Jennifer Scheer, MD 739 W Springfield Ave, Gerald, MO 63037-2135 Ph: (573) 764-3311 | Jennifer Scheer, MD 739 W Springfield Ave, Gerald, MO 63037-2135 Ph: (573) 764-3311 |
News Archive
With Covid vaccines expected to remain scarce into early spring, Connecticut has scrapped its complicated plans to prioritize immunizations for people under 65 with certain chronic conditions and front-line workers. Instead, the state will primarily base eligibility on age.
New research published online today in Blood Journal of the American Society of Hematology (ASH), challenges the generally held belief that individuals with HIV and aggressive lymphoma are not candidates for standard treatment.
We commend the U.S. House of Representatives for passing health reform legislation. Our country has a moral imperative to provide affordable access to health care, and this legislation will help do just that through significant improvements to Medicare, Medicaid and long-term care services.
The Alzheimer's Drug Discovery Foundation (ADDF) announced today that it has awarded a grant of $240,000 to AgeneBio Inc. to develop a new class of small-molecules that have promise in treating amnestic mild cognitive impairment (aMCI), a neurological condition that often progresses to Alzheimer's disease and affects more than 3 million aging Americans.
› Verified 6 days ago